New drug combo aims to tackle Hard-to-Treat cancers
NCT ID NCT03872947
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Participants receive TRK-950 plus one of several chemotherapy or immunotherapy regimens depending on their cancer type.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TRK-950
What this could lead to
If successful, this could point toward a new combination treatment option for several advanced solid tumors that are hard to treat.
What could go wrong
This is an early-phase trial, so the main goal is safety and dosing, not proof of effectiveness. The drug may not work or could cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AOA-HOPE
Tucson, Arizona, 85711, United States
-
Atlantic Health System
Morristown, New Jersey, 07960, United States
-
Centre Léon Bérard
Lyon, 69373, France
-
HOAG Memorial Hospital Presbyterian
Newport, California, 92663, United States
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Northwest Cancer Specialists
Portland, Oregon, 97227, United States
-
Ochsner Clinic Foundation
New Orleans, Louisiana, 70121, United States
-
Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute and Research Center)
Eugene, Oregon, 97401, United States
-
Perlmutter Cancer Center at NYU Langone
New York, New York, 10016, United States
-
Texas Oncology - Downtown Fort Worth Cancer Center
Fort Worth, Texas, 76104, United States
-
Texas Oncology, P.A. Baylor Charles A. Sammons Cancer Center
Dallas, Texas, 75246, United States
-
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
Virginia Cancer Specialists, PC
Leesburg, Virginia, 20176, United States